Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps

A substantial portion of asthma and nasal polyps (NPs) share a common pathogenesis, which includes type 2-mediated inflammation. Distinct endotypes and phenotypes characterizing asthma and chronic rhinosinusitis have been identified. With emerging evidence describing pathophysiology , novel targets for biologic monoclonal antibody treatments have been developed. There are currently six biologic therapies approved by the US Food and Drug Administration to treat asthma, including omalizumab , mepolizumab , reslizumab , benralizumab , dupilumab , and tezepelumab , three of these—omalizumab, mepolizumab, and dupilumab—are also approved for NPs.